Mar 9, 2022
MediSieve has been accepted onto the London and Partners Mayor's International Business Programme, supported by the Mayor of London.
MediSieve’s first product targets IL-6 cytokine to treat various hyperinflammation condition like Sepsis, COVID-19, and Cytokine Release Syndrome.
LONDON – March 09, 2022 – MediSieve has been accepted onto the London and Partners Mayor's International Business Programme, supported by the Mayor of London. The programme helps London-based scaleups expand internationally by providing access to mentorship, expert advice, virtual trade missions, focused workshops and events, as well as introductions to potential new business partners.
London & Partners is the business growth and destination agency for London. Their goal is to create resilient, sustainable and inclusive economic growth by focusing on high-growth sectors, visitor economy, London brands, partnerships and profit-making ventures. The company supports international and domestic business through investment, trade, growth and innovation programmes, as well as attracts visitors to further define London as a world-class destination, growing the city's global reputation and fuelling economic growth.
Part-funded by the European Regional Development Fund (ERDF), the Mayor’s International Business Programme helps ambitious scaleups from London’s technology, life sciences, creative and urban sectors to expand their businesses internationally. The free 12-month programme provides world class support and advice for international business success, including on-the ground support in key global markets. The MIBP welcomes a new cohort every quarter, with notable alumni including companies such as Monzo, Revolut, Elvie and Bloom & Wild. MediSieve will have its first opportunity to meet fellow cohort members, programme partners and mentors at the MIBP’s Cohort 22 Launch on the 23 of May 2022. The programme is supported by seven lead partners: Ciklum, Globalization Partners, GranTree, Microsoft, Moore Kingston Smith, Taylor Wessing and Wilson Sonsini Goodrich & Rosati.
To date, the MIBP has helped more than 1000 high-growth London companies win business in international markets, creating more than 4000 jobs for the global economy. Head of the Mayor’s International Business Programme at London & Partners, Dhaval Gore, is extremely proud to be shining a light on what London’s fastest-growing businesses have to offer overseas.
MediSieve CEO George Frodshman said:
"We are delighted to be part of the London Mayor's International Business Programme. We expect to get great value from the training and networking opportunities that the programme provides, and look forward to meeting the other participants! A big thank you to the organisers for selecting us!"
The programme will provide MediSieve with plenty of opportunities to network and attract investors throughout its duration, enabling progress and development.
More about the MIBP can be found here:
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: